Literature DB >> 8740110

The effects of ciprofloxacin on human chondrocytes in cell culture.

M A Mont1, S K Mathur, C G Frondoza, D S Hungerford.   

Abstract

Ciprofloxacin is a highly potent antibacterial agent that is used extensively in bone and joint infections. Because of reports of potential chondro-toxicity in animals, the effects of this drug on cells derived from human cartilage were tested in liquid micromass and agarose gel cultures. An inhibition of cell proliferation as indicated by a decrease in [3H]-thymidine uptake and bromodeoxyuridine labeling at ciprofloxacin concentrations of 0.5 and 50 mg/l was found which corresponded to the therapeutic and toxic serum levels. There was no effect on proteoglycan synthesis as indicated by 35SO4 incorporation. Immunocytochemistry showed no changes in morphology or staining patterns for type-I procollagen, type-II collagen, keratan sulfate and unsulfated chondroitin. Because the amount of inhibition of DNA synthesis varied with different ciprofloxacin concentrations, this data suggests that this agent has a differential effect on newly differentiating cells and might be the basis for contraindication in pediatric patients.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8740110     DOI: 10.1007/bf01713325

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  21 in total

Review 1.  Quinolone antimicrobial agents: adverse effects and bacterial resistance.

Authors:  J S Wolfson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-12       Impact factor: 3.267

2.  Juvenile canine drug-induced arthropathy: clinicopathological studies on articular lesions caused by oxolinic and pipemidic acids.

Authors:  A Gough; N J Barsoum; L Mitchell; E J McGuire; F A de la Iglesia
Journal:  Toxicol Appl Pharmacol       Date:  1979-10       Impact factor: 4.219

3.  Dedifferentiated chondrocytes reexpress the differentiated collagen phenotype when cultured in agarose gels.

Authors:  P D Benya; J D Shaffer
Journal:  Cell       Date:  1982-08       Impact factor: 41.582

Review 4.  Use of quinolones in pediatric patients.

Authors:  D Adam
Journal:  Rev Infect Dis       Date:  1989 Jul-Aug

5.  Parenteral fluoroquinolones in children with life-threatening infections.

Authors:  R Dagan; F Schlaeffer; M Einhorn
Journal:  Infection       Date:  1990 Jul-Aug       Impact factor: 3.553

6.  Ciprofloxacin: toxicologic evaluation of additional safety data.

Authors:  G Schluter
Journal:  Am J Med       Date:  1989-11-30       Impact factor: 4.965

Review 7.  New quinolones: in vitro effects as a potential source of clinical toxicity.

Authors:  A Forsgren; A Bredberg; K Riesbeck
Journal:  Rev Infect Dis       Date:  1989 Jul-Aug

8.  Nalidixic acid in children: retrospective matched controlled study for cartilage toxicity.

Authors:  U B Schaad; J Wedgwood-Krucko
Journal:  Infection       Date:  1987 May-Jun       Impact factor: 3.553

9.  4-Quinolone antibiotics: positive genotoxic screening tests despite an apparent lack of mutation induction.

Authors:  A Bredberg; M Brant; K Riesbeck; Y Azou; A Forsgren
Journal:  Mutat Res       Date:  1989-03       Impact factor: 2.433

10.  In-vitro culture of human chondrocytes from adult subjects.

Authors:  A Delbrück; B Dresow; E Gurr; E Reale; H Schröder
Journal:  Connect Tissue Res       Date:  1986       Impact factor: 3.417

View more
  3 in total

1.  Effects of ciprofloxacin and ofloxacin on adult human cartilage in vitro.

Authors:  M Menschik; J Neumüller; C W Steiner; L Erlacher; M Köller; R Ullrich; W Graninger; W B Graninger
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

2.  Proteoglycan and collagen biochemical variations during fluoroquinolone-induced chondrotoxicity in mice.

Authors:  M A Simonin; P Gegout-Pottie; A Minn; P Gillet; P Netter; B Terlain
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

3.  Fluoroquinolone use in a child associated with development of osteochondritis dissecans.

Authors:  John C Jacobs; Kevin G Shea; Julia Thom Oxford; James L Carey
Journal:  BMJ Case Rep       Date:  2014-09-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.